Brainstorm Cell Therapeutics, Inc (BCLI) concluded trading on Thursday at a closing price of $0.91, with 5.98 million shares of worth about $5.44 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -57.51% during that period and on April 10, 2025 the price saw a loss of about -18.03%. Currently the company’s common shares owned by public are about 6.14M shares, out of which, 5.07M shares are available for trading.
Stock saw a price change of -25.73% in past 5 days and over the past one month there was a price change of -41.82%. Year-to-date (YTD), BCLI shares are showing a performance of -59.76% which decreased to -89.55% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.00 but also hit the highest price of $10.05 during that period. The average intraday trading volume for Brainstorm Cell Therapeutics, Inc shares is 41.16K. The stock is currently trading -30.42% below its 20-day simple moving average (SMA20), while that difference is down -40.98% for SMA50 and it goes to -67.24% lower than SMA200.
Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) currently have 6.14M outstanding shares and institutions hold larger chunk of about 6.33% of that.
The stock has a current market capitalization of $5.96M and its 3Y-monthly beta is at 0.38. It has posted earnings per share of -$2.32 in the same period. It has Quick Ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCLI, volatility over the week remained 17.19% while standing at 10.81% over the month.
Stock’s fiscal year EPS is expected to rise by 4.33% while it is estimated to increase by 55.66% in next year. EPS is likely to shrink at an annualized rate of 27.78% for next 5-years, compared to annual growth of 32.00% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on February 04, 2021 offering a Buy rating for the stock and assigned a target price of $12 to it. On December 19, 2016, Maxim Group Reiterated their recommendations, while on December 22, 2015, Maxim Group Reiterated their ratings for the stock with a price target of $5.
